Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
Florian Kast, Martin Schwill, Jakob C. Stüber and 12 more
Nature Communications · 2021
doi:10.1038/s41467-021-23948-6 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
HER2 acts an oncogenic driver in numerous cancers. Here, the authors design an anti-HER2 biparatopic and tetravalent IgG fusion with inhibitory effects in a xenograft model.
Abstract licence: CC BY-NC-ND
References60
- 22.
- 24.
- 37.
37 more references, whose wording the paper’s licence keeps private.
All 60 referencesCited by papers we hold1
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.